Abstract
Objective
Inflammatory stimuli inducing epithelial-to-mesenchymal transition (EMT) can transdifferentiate mesenteric mesothelial cells into macrophages.
Methods
Sprague Dawley rat mesenteric mesothelial cells were used as a model. 1 ml Freund adjuvant was injected into the peritoneal cavity of rat and GM-CSF treatment was used to induce inflammation. IL-10 and IL-6 expression were studied by immunocytochemistry and Western blot analysis both in vivo and in vitro.
Results
Control mesothelial cell express anti-inflammatory IL-10, but no pro-inflammatory IL-6 expression could be detected in them. By the time of inflammation, IL-6 expression increased (reached the maximum level at the fifth day of inflammation), parallel to this the IL-10 entirely disappeared from these cells. In vitro GM-CSF treatment resulted in similar changes. As the mesothelial cells started to recover (at the eighth day of inflammation) IL-6 expression decreased and IL-10 level started to increase again.
Conclusion
These data show that under inflammatory stimuli mesothelial cells—like macrophages—can produce pro-inflammatory cytokines.
Keywords: Mesothel/macrophage transition, Inflammation, Inflammatory cytokines
Introduction
Monocytes and macrophages play important role in immune responses. Under healthy conditions large number of these phagocytic cells reside in the peritoneal cavity as self-sustaining resident macrophages [1, 2]. During inflammation a heterogeneous population of phagocytes appear in the peritoneal cavity [3]. It seems likely that besides of activated tissue-resident, and infiltrating monocyte-derived macrophages, cells originating from non-hemopoietic sources should also contribute to this subset of macrophages.
Earlier we proved, that inflammation transdifferentiated mesenteric mesothelial cells into macrophages-like cells. During this transition mesothelial cells expressed ED1 (pan-macrophage marker), they intensively phagocytosed ink- and bio-particles [4]. Similar changes could be observed when primary mesenteric cultures were treated with granulocyte–macrophage colony-stimulating factor (GM-CSF), which promotes the survival and activation of granulocytes, macrophages as well as dendritic cell differentiation in vivo, stimulates proliferation of several non-hemopoietic cell types [5]. In recent work, we followed the expression of pro- (IL-6) and anti-inflammatory cytokines (IL-10) in mesenteric mesothelial cells.
Materials and methods
1 ml complete Freund’s adjuvant (Sigma, Saint Louis, Missouri) was injected into the peritoneal cavity of male rats (200–250 g). Mesentery was isolated from control and treated animals (10 animals per group). For in vitro experiments, mesentery was cut out from control animals, maintained in Dulbecco’s Modified Eagle Medium (Nutrient Mixture F-12 (DMEM/F12, Life Technologies, Paisley, UK) and were treated with 1 ng/ml GM-CSF (Sigma, Saint Louis, Missouri) for 3 days. For immunolabeling, we applied a modified Tokuyashu technique [6]. The 0.6-µm-thick frozen sections were cut by Leica Ultracut S ultramicrotome (Vienna, Austria).
For immunocytochemistry, anti-IL-6 (1:100 ABCAM, Cambridge, UK), and anti-IL-10 (1:500 ABCAM, Cambridge, UK) were used as primary antibodies, anti-mouse and anti-rabbit IgG Alexa Fluor 488 (1:200, Molecular Probes, Leiden, The Netherlands) were applied as secondary antibodies. The nuclei were stained with DAPI (Vector Laboratories Inc. Burlingame, California). The samples were observed with Zeiss LSM 780 confocal microscope. Images were performed by Photoshop Elements 15 Editor.
Western blot analysis
The Western blot analysis was performed as it was previously described [4, 7]. Band densities were measured by the ImageJ software (U.S. National Institutional of Health, Bethesda, Maryland) and analyzed by the Microsoft Excel 2013 program.
Results
Control mesothelial cell expresses anti-inflammatory IL-10 (Fig. 1g), but no pro-inflammatory IL-6 expression could be detected in them (Fig. 1a). At the third day of inflammation, the mesothelial cells started to express IL-6 (Fig. 1b), reached the maximum level at the peak time of inflammation (fifth day; Fig. 1c). As the mesothelial cells started to recover (at the 8th day of inflammation), IL-6 expression decreased (Fig. 1d) and practically no IL-6 expression was detected in mesothelial cells at 11th day (Fig. 1e). In contrast to this, no IL-10 could be detected at the peak time of inflammation (Fig. 1i), but its level increased again after the eighth day of inflammation. (Fig. 1j). Our Western blot results supported these immunocytochemical observations (Fig. 1f, l). In vitro GM-CSF treatment resulted in similar changes in mesothelial cells (Fig. 1m–p).
Discussion
Monocytes and macrophages are the main sources of the inflammatory cytokines, but activated lymphocytes, fibroblasts and endothelial cells can also produce them [8]. To provide additional data about mesothelial cells/macrophage transition, we investigated the expression of IL-6 and IL-10. Our recent results show that healthy mesenteric mesothelial cells express IL-10, the main suppressor of macrophage activation. No IL-6 expression could be detected in them. Under inflammatory stimuli and GM-CSF treatment, IL-10 expression significantly diminished in these cells, and they started to produce IL-6, indicating that inflammation and GM-CSF treatment induced macrophage-like phenotypic change in them. Macrophages are the major producers of tumor necrosis factor, TNFα as well [9]. We also proved that inflammation induced TNFα expression in mesenteric mesothelial cells reaching the highest level at the peak time of inflammation [4]. Control mesothelial cells did not express EGR1, one of the main regulator of TNFα production, and monocyte–macrophage differentiation [10–12], but by the time of inflammation EGR1 expression increased significantly in them and it was translocated into the nuclei of these cells [4]. All these data strongly support the idea that under inflammatory stimuli mesothelial cells can transdifferentiate into macrophages.
Conclusion
Hereby, we provide further evidence about transdifferentiation of mesothelial cells to macrophages. These transformed mesothelial cells largely contribute to macrophage population, appearing in large number in the peritoneal cavity during inflammation.
Acknowledgements
Open access funding provided by Semmelweis University (SE).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All the procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Ginsel LA, Rijfkogel LP, Deams WT. A dual origin of macrophages? Macrophage Biol Rev Hypothesis. 1985;5:621–649. [Google Scholar]
- 2.De Bakker JM, de Wit AW, Woelders H, Ginsel LA, Deams WT. On the origin of peritoneal resident macrophages. II. Recovery of the resident macrophage population in the peritoneal cavity and milky spots after peritoneal cell depletion. J Submicrosc Cytol. 1985;7:41–151. [PubMed] [Google Scholar]
- 3.Papadimitriou JM, Ashman RB. Macrophages: current view on their differentiation, structure and function. Ultrastruct Pathol. 1989;13:343–372. doi: 10.3109/01913128909048488. [DOI] [PubMed] [Google Scholar]
- 4.Katz S, Zsiros V, Dóczi N, Kiss AL. Inflammation-induced epithelial-to-mesenchymal transition and GM-CSF treatment stimulate mesenteric mesothelial cells to transdifferentiate into macrophages. Inflammation. 2018. [DOI] [PubMed]
- 5.Rasko JEJ, Grough MM. Granulocyte macrophage-colony stimulating factor. In: Thomson AW, editor. Cytokine handbook. 2. New York: Academic Press; 1994. pp. 342–369. [Google Scholar]
- 6.Slot JW, Geuze HJ. Cryosectioning and immunolabeling. Nat Protoc. 2007;2:2480–2491. doi: 10.1038/nprot.2007.365. [DOI] [PubMed] [Google Scholar]
- 7.Olson BJ, Markwell J. Assays for determination of protein concentration. Curr Protocols Protein Sci. 2007. 10.1002/0471140864.ps0304s48. [DOI] [PubMed]
- 8.Duque GA, Descoteaux A. Macrophage cytokines: involvement in immunity and infection diseases. Front Immunol. 2014;5:1–12. doi: 10.3389/fimmu.2014.00491. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20(2):87–103. doi: 10.1615/CritRevEukarGeneExpr.v20.i2.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Carter JH, Tourtellotte WG. Early response transcriptional regulators are dispensable for macrophage differentiation. J Immunol. 2007;178:3038–3047. doi: 10.4049/jimmunol.178.5.3038. [DOI] [PubMed] [Google Scholar]
- 11.Baron V, Adamson ED, Calogero A, Ragona GF, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53 and fibronectin. Cancer Gene Ther. 2006;13:115–124. doi: 10.1038/sj.cgt.7700896. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Nguyen HQB, Hoffman-Liebermann B, Liebermann DA. The zinc finger transcription factor EGR-1 is essential for and restricts differentiation along macrophage lineage. Cell. 1993;72:197–209. doi: 10.1016/0092-8674(93)90660-I. [DOI] [PubMed] [Google Scholar]